Action against Respondent, a biotechnology company, for alleged failure to implement and maintain sufficient Internal Control Financial Reporting.   According to the SEC, Respondent’s Forms 10-K disclosed material weaknesses related to financial statements and reporting over a period of nine years, including inadequate segregation of financial duties, but provided insufficient information about the specific weaknesses.  Respondent has agreed to pay a civil penalty of $35,000.

SEC Order

SEC Press Release